Abstract: OBJECTIVE To study the correlation between glucocorticoid dosage and time and pulmonary fungal infection in patients with rheumatoid arthritis (RA), in order to provide the basis for the clinical application of glucocorticoid. METHODS The clinical data of 85 cases of RA patients from Jun. 2013 to Apr. 2016 in our hospital were analyzed retrospectively, pulmonary fungal infection of patients were recorded, the effects of general information on the infection rate were compared, and the effects of the cumulative glucocorticoid treatment time and daily glucocorticoid dosage on pulmonary fungal infection within 3 weeks were analyzed by the ROC curve. RESULTS In 85 cases of RA patients, 32 cases of patients occurred pulmonary fungal infection, with the infection rate of 37.65%. The cumulative treatment time in patients with glucocorticoid and glucocorticoid daily usage in patients with pulmonary fungal infection were significantly higher than those in uninfected patients (P<0.05). The area under the ROC curve of predicting pulmonary fungal infection in patients with RA estimated by the cumulative glucocorticoid medication time was 0.739 (P<0.05). The area under the ROC curve of predicting pulmonary fungal infection in patients with RA estimated by the average daily dose of glucocorticoid was 0.857 (P<0.05). CONCLUSION Long-term, intensive use of glucocorticoids may increase the risk of pulmonary fungal infection in patients with rheumatoid arthritis, so it needs to pay attention to the rational use of corticosteroids for the clinical treatment of patients with rheumatoid arthritis, to avoid the occurrence of pulmonary fungal infection in patients.